标题
Second-line treatments of small-cell lung cancers
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 17, Issue 11, Pages 1033-1043
出版商
Informa UK Limited
发表日期
2017-08-29
DOI
10.1080/14737140.2017.1372198
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
- (2016) Dimitrios T. Trafalis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
- (2016) Koichi Goto et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
- (2016) Giorgio Scagliotti et al. LUNG CANCER
- A phase II study of nintedanib in patients with relapsed small cell lung cancer
- (2016) Ji-Youn Han et al. LUNG CANCER
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- (2016) Alberto A. Chiappori et al. ONCOLOGIST
- A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
- (2016) Thomas W. Lycan et al. PLoS One
- A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
- (2016) Tak Yun et al. Cancer Research and Treatment
- Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005
- (2015) Madhusmita Behera et al. CANCER
- Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer
- (2015) Wataru Nakajima et al. CANCER BIOLOGY & THERAPY
- Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501
- (2015) Radj Gervais et al. Clinical Lung Cancer
- Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
- (2015) Tracey L. Evans et al. Journal of Thoracic Oncology
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer
- (2014) Jeffrey W. Allen et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
- (2014) Philip E. Lammers et al. Journal of Thoracic Oncology
- Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
- (2014) Marjorie G. Zauderer et al. LUNG CANCER
- Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
- (2014) Cassandra L Hodgkinson et al. NATURE MEDICINE
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
- (2013) David R. Spigel et al. Clinical Lung Cancer
- A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
- (2013) Filippo de Marinis et al. Journal of Thoracic Oncology
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
- (2012) M. C. Pietanza et al. CLINICAL CANCER RESEARCH
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study
- (2012) Claudio Dazzi et al. Clinical Lung Cancer
- Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer
- (2012) Jian-Mei Hou et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients
- (2012) Gun Min Kim et al. Journal of Thoracic Oncology
- A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
- (2012) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
- (2012) Giannis Mountzios et al. LUNG CANCER
- A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
- (2012) Ji-Youn Han et al. LUNG CANCER
- Notch signaling in human development and disease
- (2012) Andrea L. Penton et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents
- (2011) Deborah R. Wysong et al. CELL CYCLE
- Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer
- (2011) Lee M. Krug et al. Journal of Thoracic Oncology
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
- (2011) Maria Q. Baggstrom et al. Journal of Thoracic Oncology
- Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
- (2011) Takashi Hirose et al. LUNG CANCER
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- (2011) Paul K. Paik et al. LUNG CANCER
- Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
- (2010) Nikolaos Xenidis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
- (2010) A. Tarhini et al. CLINICAL CANCER RESEARCH
- Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial
- (2010) Mark A. Socinski et al. Journal of Thoracic Oncology
- Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study
- (2010) Shadia Jalal et al. Journal of Thoracic Oncology
- Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
- (2010) Antonius A. Miller et al. Journal of Thoracic Oncology
- Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group
- (2010) Shadia Jalal et al. Journal of Thoracic Oncology
- Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial
- (2010) Barbara J. Gitlitz et al. Journal of Thoracic Oncology
- Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
- (2010) Jaeheon Jeong et al. LUNG CANCER
- A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer
- (2010) Chin Kook Rhee et al. LUNG CANCER
- Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
- (2009) John R. Eckardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral second- and third-line lomustine–etoposide–cyclophosphamide chemotherapy for small cell lung cancer
- (2009) Bernard Lebeau et al. LUNG CANCER
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- (2009) Erin D. Pleasance et al. NATURE
- Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy
- (2008) Young Hak Kim et al. CANCER
- Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer
- (2008) A. Tatematsu et al. CLINICAL CANCER RESEARCH
- A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
- (2008) Bjørn H. Grønberg et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search